Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Richard Mazzarella who wrote (9114)	5/1/1998 10:08:00 AM
From: Leman	Respond to of 14328

check out this machineFriday May 1, 8:00 am Eastern Time Company Press Release Medstone Receives Recommendation For Approval From FDA Panel For Treatment of Gallstones ALISO VIEJO, Calif.--(BW HealthWire)--May 1, 1998--Medstone International Inc. (Nasdaq: MEDS - news) has been notified that the FDA's Gastroenterology and Urology Device Advisory Panel has recommended conditional approval of Medstone's submission to treat gallstones using the company's lithotripter, in combination with Actigall, a drug used to dissolve gallstones. The condition to approval is that Medstone performs a post-approval study. ''The recommendation for approval is another step along the approval trail. This step was taken after many years of hard work by a group of talented people. We believe this combined therapy will be a valuable tool for the physicians in treating certain patients with gallstones,'' said David V. Radlinski, chairman and chief executive officer. Medstone, as the only vertically integrated extracorporeal shockwave therapy (''ESWT'') company, is focused on providing cost effective lithotripsy for treatment of various diseases. Contact: Medstone International Inc.